Shuting Lai

Title: Shuting Lai: Innovator in Gastro-Retentive Drug Delivery Systems

Introduction

Shuting Lai is a notable inventor based in Guangdong, China. She has made significant contributions to the field of pharmaceuticals, particularly in the development of drug delivery systems. Her innovative work focuses on enhancing the bioavailability and effectiveness of medications.

Latest Patents

Shuting Lai holds a patent for a lenalidomide gastro-retentive sustained-release tablet and its preparation method. The invention discloses a sustained-release tablet that comprises 3 wt % to 14 wt % of lenalidomide, 14 wt % to 68 wt % of a release enhancer with low bulk density, and 23 wt % to 70 wt % of a sustained-release material with low bulk density. The formulation ensures that the tablet remains in a floating state within the gastric environment, thereby improving drug retention and bioavailability while minimizing side effects.

Career Highlights

Shuting Lai is associated with Diqi Pharmaceuticals Co., Ltd., where she continues to advance her research and development efforts. Her work has been instrumental in creating innovative pharmaceutical solutions that address critical healthcare needs.

Collaborations

Shuting Lai collaborates with esteemed colleagues, including Feng Liu and Huafeng Luo, to further enhance the impact of her research in the pharmaceutical industry.

Conclusion

Shuting Lai's contributions to the field of gastro-retentive drug delivery systems exemplify her commitment to innovation in pharmaceuticals. Her work not only improves medication efficacy but also enhances patient outcomes.